Crescita Therapeutics Reports 2019 First Quarter Results

Wednesday, May 15, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

EBITDA and Adjusted EBITDA Reconciliation

In thousands of CAD dollars

Three months ended March 31,

2019

2018

Change

Net income (loss) 

42

(424)

466

Add:

Depreciation and amortization

356

290

66

Interest expense, net

124

139

(15)

Deferred income tax expense

236

-

236

EBITDA

758

5

753

Equity-settled stock-based compensation

133

82

51

Foreign currency loss

65

-

65

Less:

Foreign currency gain

-

4

(4)

Adjusted EBITDA

956

83

873



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store